4/ Many big questions remain: ideal platforms, personalized vs. off-the-shelf approaches, optimal combinations, and more. The next few years are critical, with multiple pivotal trials expected to report soon

2/ Earlier approaches—vaccines targeting overexpressed self-antigens as monotherapy in late-line disease—failed due to immune tolerance, weak immunogenicity, and exhaustion.
Clinically, it was akin to giving COVID vaccine to someone in the ICU with severe COVID

🚨 New manuscript led by Marina Baretti

Using #CODEX multiplexed imaging:

🧬 #CCA is rich in CAFs,TAMs,MDSCs, scarce CD8 T cells (~1.8% of all cells)
🧬 FGFR2 fusions → ⬆️ CD11b+/CD15+ granulocytes
🧬 IDH1 mutations → trend ⬆️M2-like mac

▶️ pubmed.ncbi.nlm.nih.gov/39969434/

Our first 2025 paper was published today in JITC

Explores the "obesity paradox" in cancer immunotherapy:

1️⃣ Obese patients have better IO outcomes (despite ⬆️cancer risk)
2️⃣ Obesity → ⬆️T-cell exhaustion →⬆️ ICI benefit
doi.org/10.1136/jitc...

Excited to share our latest study in Nature Immunology on TLS in #HCC patients treated w/ neoadj ICB:
⏩ TLS linked to improved outcomes
⏩ Novel "involuted" TLS found in tumor regression zones
🔗 nature.com/articles/s41...